Fulltext present in this item

Thumbnail
Fulltext: 88640.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Development of radiotracers for the determination of the beta-cell mass in vivo.
Author(s): Brom, M. ; Andralojc, K.M. ; Oyen, W.J.G. ; Boerman, O.C. ; Gotthardt, M.
Publication year: 2010
Source: Current Pharmaceutical Design, vol. 16, iss. 14, (2010), pp. 1561-1567
ISSN: 1381-6128
DOI: https://doi.org/10.2174/138161210791164126
Annotation: 1 mei 2010
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/88640   https://hdl.handle.net/2066/88640

Display more details
Subject: IGMD 1: Functional imaging
Organization: Nuclear Medicine
Journal title:
Current Pharmaceutical Design
Volume: vol. 16
Issue: iss. 14
Page start: p. 1561
Page end: p. 1567
Abstract:
The changes in beta-cell mass (BCM) during the course of diabetes are not yet well characterized. A non-invasive method to measure the BCM in vivo would allow us to study the BCM during the onset and progression of the diseases caused by beta-cell dysfunction. PET and SPECT imaging are attractive approaches to determine the BCM because of their high sensitivity and the possibility to quantitatively analyze the images. Several targets and their corresponding radiotracers have been examined for their ability to determine the BCM including radiolabeled antibodies, antibody fragments, peptides and small molecules. Although some of these tracers show promising results, there is still no reliable method to determine the beta-cell mass in vivo. In this review, the targets and the corresponding radiotracers evaluated so far for the determination of the BCM in vivo in humans will be discussed.

This item appears in the following Collection(s)

Browse

Statistics